Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.

Diala El-Maouche Samira M Sadowski Georgios Z Papadakis Lori Guthrie Candice Cottle-Delisle Roxanne Merkel Corina Millo Clara C Chen Electron Kebebew Michael T Collins

J Clin Endocrinol Metab

Division of Endocrinology (D.E.-M.), Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida; Skeletal Clinical Studies Unit (D.E.-M., L.G., M.T.C.), Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland; Thoracic and Endocrine Surgery (S.M.S.), University Hospitals of Geneva, Geneva, Switzerland; The Endocrine Oncology Branch (S.M.S., C.C.-D., R.M., E.K.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Positron Emission Tomography Department (G.Z.P., C.M.), Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, Maryland; Nuclear Medicine Division (C.C.C.), Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.

Published: October 2016

There are special tumors called phosphaturic mesenchymal tumors (PMTs) that can be hard to find.
Scientists are using a type of scanning called Ga-DOTATATE PET/CT to help spot these tumors in patients with a condition called tumor-induced osteomalacia (TIO).
In a study, Ga-DOTATATE was successful in finding the tumors in most patients, proving it might be the best way to locate PMTs compared to other types of scans.

Context: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using Gallium (Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors.

Objective: Our objective was to evaluate the use of Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO).

Design: This was a single-center prospective study of patients with TIO.

Setting: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015.

Subjects: Eleven subjects (six females, five males) with TIO were included.

Intervention: Subjects underwent Ga-DOTATATE PET/CT in addition to In-pentetreotide single-photon emission CT (Octreoscan- SPECT/CT) and fluorodeoxyglucose-PET/CT (F FDG-PET/CT) scan.

Main Outcome Measures: Localization of PMTs on the previously described imaging modalities were determined.

Results: The tumor was successfully localized in 6/11 (54.5%) subjects (one was metastatic). The tumor was identified by Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and F FDG-PET each identified the tumor in 4/6. In no cases was Ga-DOTATATE the only imaging study to identify the tumor.

Conclusions: In this first prospective study comparing Ga-DOTATATE PET/CT to Octreoscan-SPECT/CT and F FDG-PET in TIO localization, Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052344	PMC
http://dx.doi.org/10.1210/jc.2016-2052	DOI Listing

Publication Analysis

Top Keywords

ga-dotatate pet/ct

tumor localization

localization tumor-induced

tumor-induced osteomalacia

prospective study

localization pmts

octreoscan-spect/ct fdg-pet

ga-dotatate

localization

study

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!